The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial launches in 2015, but only a handful of approvals.
read full article ›That Apple ($APPL) watch you are wearing may allow you to text and listen to music, and it can track your activity. But it may also be conducting a postmarket study that will help cut the price of some of your prescription drugs in the future.
read full article ›Gilead Sciences Inc. and AbbVie Inc. continue to vie for preferred coverage of their HCV drugs in the U.S. private payer market, and Gilead is out to an early lead when it comes to total lives covered. But much of the population is still up for grabs, and the real victor in share of lives could be determined by how the U.S. Department of Veterans Affairs and Medicaid plans respond.
read full article ›How Sanofi should think about pricing/rebates for first-to-market PCSK9 inhibitor
read full article ›Hepatitis C drugs may have provided the spark, but cost-pressured payors, empowered consumers, and at-risk providers are adding fuel to the drug pricing fire. The game may be up for pharma firms that try to push prices out of line with perceived value, potential patient volumes, and affordability.
read full article ›Memorial Sloan Kettering’s Peter Bach unveils a web-based drug pricing tool that uses several value measurements, including R&D investment and novelty, to identify the appropriate price for cancer drugs.
read full article ›As prices for specialty drugs like oncologics soar, outrage is mounting over the cost of the new therapies, prompting a debate about their value. Could any of this spill over to medical devices?
read full article ›Personal health information is the new currency of drug development and commercialization. Novel collaborations are helping pharmaceutical and life sciences companies maximize the value of new medicines.
read full article ›Why Novartis likes outcomes-based payment for Entresto in heart failure
read full article ›Gilead Sciences recently began limiting enrollment in its Sovaldi and Harvoni patient assistance program in an attempt to pressure payors to expand their coverage criteria. The big question is how payors are likely to react.
read full article ›